Apoptosis: A clinically useful measure of antiretroviral drug toxicity? Apoptosis: A clinically useful measure of antiretroviral drug toxicity? Hooker & Cherry

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1543-1553

  Hooker, David James ^a   Cherry, Catherine Louise ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

Antiretroviral drugs; Apoptosis; Biomarker; Drug toxicity; HAART; HIV; MtDNA; NRTI

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LACTIC ACID; MITOCHONDRIAL DNA; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADIPOSE TISSUE; APOPTOSIS; BIOASSAY; BIOPSY; CARDIOMYOPATHY; DRUG EXPOSURE; DRUG SAFETY; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MEGALOCYTOSIS; MYOPATHY; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; REVIEW;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; BIOMARKERS, PHARMACOLOGICAL; DRUG MONITORING; HIV INFECTIONS; HUMANS;

EID: 71049179805     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903282781     Document Type: Review

References (137)

1. Fang C, Chang Y, Hsu H, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007;100(2):97-105 (Pubitemid 46332120)
2. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47(6):825-833
3. Correll P, Law M, McDonald A, et al. HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998;169:469-472
4. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997;315:1194-1199
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997;11:F101-5
6. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. NEJM 1998;338:853-860
7. Nolan D, Hammond E, James I, et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003;8(6):617-626
8. Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007;8(6):367-373
9. Nakasujja N, Musisi S, Robertson K, et al. Human immunodeficiency virus neurological complications: an overview of the Ugandan experience. J Neurovirol 2005;1(S3):26-29
10. Forna F, Liechty C, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;44(4):456-462
11. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003;3:293-301
12. Pujari S, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39(2):199-202
13. Morse C, Kovacs J. Metabolic and skeletal complications of HIV infection: the price of success. JAMA 2006;296(7):844-854
14. van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Top Med Hyg 2007;101(8):793-798
15. Lima V, Hogg R, Harrigan P, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21(6):685-692
16. Hogg R, Lima V, Sterne JA, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372(9635):293-299
17. Haubrich R, Riddler SA, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-1118
18. Brinkman K, ter Hofstede J, Burger D, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744
19. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354(9184):1112-1115
20. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-422
21. Chen C, Vazquez-Padua M, Cheng Y. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-628
22. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32
23. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-797
24. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:795-797
25. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatric Infect Dis J 2003;22:778-782
26. Tan D, Walmsley S, Shen S, Raboud J. Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors. HIV Clin Trials 2006;7(3):107-115
27. Marceau G, Sapin V, Jacomet C, et al. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients. Clin Chem 2003;49(7):1154-1162
28. Tesiorowski AM, Harris M, Chan KJ, et al. Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy [letter]. J Acquir Immune Defic Syndr 2002;31:250-251 (Pubitemid 35190581)
29. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002;16:1341-1349
30. Huynh TK, Luttichau HR, Roge BT, Gerstoft J. Natural history of hyperlactataemia in Human Immunodeficiency Virus-1-infected patients during highly active antiretroviral therapy. Scand J Infect Dis 2003;35:62-66
31. Wester C, Okezie O, Thomas A, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007;46(3):318-322
32. Songa P, Castelnuovo B, Mugasha E, et al. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007;45(4):514-517
33. Bolhaar M, Karstaedt A. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007;45(2):254-260
34. Milazzo L, Piazza M, Sangaletti O, et al. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2004;55(1):84-89
35. Sternfeld T, Lorenz A, Schmid M, et al. Increased red cell corpuscular volume and hepatic mitochondrial function in NRTI-treated HIV infected patients. Curr HIV Res 2009;7(3):336-339
36. Gahan M, Miller F, Lewin S, et al. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. J Clin Virol 2001;22(3):241-247
37. Zhang H, Cooney DA, Sreenath A, et al. Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content. Mol Pharmacol 1994;46:1063-1069
38. Gourlain K, Amellal B, Ait Arkoub Z, et al. Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Med 2003;4:287-292
39. Hammond EL, Sayer D, Nolan D, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003;27(1):97-110
40. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346(11):811-820
41. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-1809
42. McComsey G, Tan D-J, Lederman M, et al. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002;15(4):513-518
43. Cherry C, Nolan D, James I, et al. Tissue specific associations between mitochondrial DNA levels and current treatment status in HIV infected individuals. J Acquir Immune Defic Syndr 2006;42(4):435-440
44. López S, Miró O, Martínez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004;9(1):47-55
45. Reiss P, Casula M, de Ronde A, et al. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine + didanosine or zidovudine + zalcitabine) vs single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004;5(1):11-14
46. De Mendoza C, de Ronde A, Smolders K, et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20(3):271-273
47. Hoy J, Gahan M, Carr A, et al. Changes in mitochondrial DNA in PBMCs from patients with HIV lipoatrophy randomized to abacavir. J Infect Dis 2004;190(4):688-692
48. Cote HC, Yip B, Asselin JJ, et al. Mitochondrial:nuclear DNA ratios in peripheral blood cells from Human Immunodeficiency Virus-infected patients who received selected HIV antiretroviral drug regimens (brief report). J Infect Dis 2003;187(12):1972-1976
49. De Felipe B, Blanco A, Soriano-Sarabia N, et al. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels. Infection 2008;36(3):266-270
50. Cherry C, Gahan M, Lewin S, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002;30:271-277
51. Nolan D, Hammond EL, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338
52. Walker UA, Bickel M, Volksbeck S, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue from HIV-infected patients. J Acquir Immune Defic Syndr 2002;29:117-121
53. Kim MJ, Jardel C, Barthélémy C, et al. Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy. Antimicrob Agents Chemother 2008;52(5):1670-1676
54. Shikuma C, Gerschenson M, Chow D, et al. Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retroviruses 2008;24(10):1255-1262
55. Lin C, Sloan D, Dang C, et al. Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells. Cytometry B Clin Cytom 2009;76(3):181-190
56. Mallon PWG, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of mitochondrial DNA depletion. J Infect Dis 2005;191(10):1686-1696
57. Sievers M, Walker U, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 2009;200(2):252-262
58. Vaux D, Korsemeyer S. Cell death in development. Cell 1999;96:245-254
59. Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462
60. Vlahakis S, Bennett S, Whitehead S, Badley A. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007;12(5):969-977
61. Karamchand L, Dawood H, Chuturgoon A. Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients. J Acquir Immune Defic Syndr 2008;48(4):381-388
62. Viora M, Di Genova G, Rivabene R, et al. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int J Immunopharmacol 1997;19(6):311-321
63. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999;13:2261-2267
64. Pettersen J, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus / acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59(5):816-824
65. Purevjav E, Nelson D, Varela J, et al. Myocardial fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc Toxicol 2007;7:255-263
66. Lloreta J, Domingo P, Pujol RM, et al. Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Arch 2002;441(6):599-604
67. Cherry C, Lal L, Thompson K, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patients from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005;38(3):263-267
68. Rizza S, Badley A. HIV protease inhibitors impact on apoptosis. Med Chem 2008;4(1):75-79
69. Badley A. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 2005;12(Suppl 1):924-931
70. Cooper C, Phenix B, Mbisa G, et al. Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo. Front Biosci 2004;9:338-341
71. Lichtner M, Mengoni F, Mastroianni C, et al. HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. Apoptosis 2006;11(5):781-787
72. Wasmuth J, Hackbarth F, Rockstroh J, et al. Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy. HIV Med 2003;4(2):111-119
73. Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-1883 (Pubitemid 28279721)
74. Schambelan M, Benson C, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-275
75. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-1667
76. McComsey G, Paulsen D, Lonergan J, et al. Improvements in lipoatrophy, mitochondrial DNA content and adipose tissue apoptosis levels after replacement of stavudine with either abacavir or zidovudine. AIDS 2005;19:15-23
77. Domingo P, Matías-Guiu X, Pujol R, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001;184:1197-1201
78. Zhang S, Carper M, Lei X, et al. Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion. Am J Physiol Endocrinol Metab 2009;296(4):E925-35
79. Singh VP, Bren GD, Algeciras-Schimnich A, et al. Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol 2009;296(5):G1040-6
80. Robinson B, Li Z, Nath A. Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J Neurovirol 2007;13:160-167
81. Dalakas M, Illa I, Pezeshkpour G, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-1105 (Pubitemid 20149526)
82. Masanes F, Barrientos A, Cebrian M, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998;159:226-228
83. Group DS, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356(17):1723-1735
84. Baliga R, Liu C, Hoyt D, et al. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol 2004;4(2):199-206
85. Shedlock DJ, Hwang D, Choo AY, et al. HIV-1 viral genes and mitochondrial apoptosis. Apoptosis 2008;13(9):1088-1099
86. Miura Y, Koyanagi Y. Death ligand-mediated apoptosis in HIV infection. Rev Med Virol 2005;15(3):169-178
87. Gougeon ML, Piacentini M. New insights on the role of apoptosis and autophagy in HIV pathogenesis. Apoptosis 2009;14(4):501-508
88. Westendorp M, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995;375:497-500
89. Ayyavoo V, Mahboubi A, Mahalingam S, et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 1997;3:1117-1123
90. Conti L, Rainaldi G, Matarrese P, et al. The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med 1998;187:403-413
91. Stewart S, Poon B, Jowett J, Chen I. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997;71:5579-5592
92. Okada H, Takei R, Tashiro M. HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). FEBS Lett 1997;414:603-606
93. Ganghi R, Chen B, Straus S, et al. HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med 1998;187:1113-1122
94. Herbein G, Van Lint C, Lovett J, Verdin E. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and uninfected bystander T lymphocytes. J Virol 1998;72:660-670
95. Bonyhadi M, Rabin L, Salimi S, et al. HIV induces thymus depletion in vivo. Nature 1993;363:728-732
96. Stanley S, McCune J, Kaneshima H, et al. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med 1993;178:1151-1163
97. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231(4740):850-853
98. Groux H, Torpier G, Monte D, et al. Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331-340
99. Muro-Cacho C, Pantaleo G, Fauci A. Analysis of apoptosis in lymph nodes of HIV-infected persons. J Immunol 1995;154:5555-5566
100. Douek D, Brenchley J, Betts M, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417(6884):95-98
101. Haase A. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005;5:783-792
102. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371
103. Boudet F, Lecoeur H, Gougeon M-L. Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. J Immunol 1996;156:2282-2293
104. Amendola A, Gougeon M, Poccia F, et al. Induction of "tissue" transglutaminase in HIV pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues. Proc Natl Acad Sci USA 1996;93:11057-11062
105. Espert L, Denizot M, Grimaldi M, et al. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J Clin Invest 2006;116:2161-2172
106. Perfettini J, Castedo M, Nardacci R, et al. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med 2005;201:279-289
107. Perfettini J, Roumier T, Castedo M, et al. NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J Exp Med 2004;199:629-640
108. González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005;5:69-81
109. Thompson K, McArthur JC, Wesselingh SL. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol 2001;49(6):745-752
110. Isgrò A, Mezzaroma I, Aiuti A, et al. Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy. AIDS 2004;18(9):1335-1337
111. Keswani S, Pardo C, Cherry C, et al. HIV-associated sensory neuropathies. AIDS 2002;16(16):2105-2117
112. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in Human Immunodeficiency Virus infection. J AIDS 1995;9:153-161
113. Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health 2005;2(3):153-163
114. Khosravi-Far R, Esposti M. Death receptor signals to mitochondria. Cancer Biol Ther 2004;3:1051-1057
115. Lecoeur H, Melki M, Saïdi H, Gougeon M. Analysis of apoptotic pathways by multiparametric flow cytometry: application to HIV infection. Methods Enzymol 2008;442:51-82
116. Macho A, Decaudin D, Castedo M, et al. Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry 1996;25:333-340
117. Castedo M, Hirsch T, Susin S, et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996;157:512-521
118. Oubrahim H, Stadtman E, Chock P. Mitochondria play no roles in Mn(II)-induced apoptosis in HeLa cells. PNAS 2001;98:9505-9510
119. Hooker D, Gorry P, Ellett A, et al. Measuring and monitoring apoptosis and drug toxicity in HIV patients by ligation-mediated polymerase chain reaction. J Cell Mol Med 2009;13(5):948-958
120. Tian Q, Streuti M, Siato H, et al. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-639
121. Kelly K, Sandoval R, Dunn K, et al. A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol 2003;284(5):C1309-18
122. Gavrieli Y, Sherman Y, Ben-Sasson S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501
123. Yasuda M, Umemura S, Osamura R, et al. Apoptotic cells in the human endometrium and placental villi: pitfalls in applying the TUNEL method. Arch Histol Cytol 1995;58:185-190
124. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22(4):499-511
125. Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem 2004;37(7):605-617
126. Kobayashi Y, Mori M, Naurto T, et al. Dynamic movement of cytochrome c from mitochondria into cytosol and peripheral circulation in massive hepatic cell injury. Pediatr Int 2004;46:685-692
127. Miller T, Knapton A, Adeyemo O, et al. Cytochrome c: a non-invasive biomarker of drug-induced liver injury. J Appl Toxicol 2008;28:815-828
128. Biven K, Erdal H, Hagg M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003;8(3):263-268
129. Cummings J, Ranson M, Lacasse E, et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2006;95(1):42-48
130. Holdenrieder S, Stieber P, Bodenmuller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001;95(2):114-120
131. Kerr J, Harmen B. Definition and incidenceof apoptosis, an historical perspective, in apoptosis: the molecular basis of cell death. In: Tomei L, Cope F, editors, Cold Spring Harbor Laboratory Press: New York; 1991. p. 5-29
132. Kerr J, Searle J, Harmen B, Bishop C. Apoptosis, in perspectives on mammalian cell death. In: Potten C, editor, Oxford University Press: Oxford; 1987. p. 93-128
133. Martz E, Howell D. CTL: virus controls cells first and cytolytic cells second? DNA fragmentation, apoptosis and the prelytic halt hypothesis. Immunol Today 1989;10:79-86
134. Shi Y, Szalay M, Paskar L, et al. Activation-induced cell death in T cell hybridomas is due to apoptosis. J Immunol 1990;144:3326-3333
135. Staley K, Blaschke A, Chun J. Apoptotic DNA fragmentation is detected by a semi-quantitative ligation-mediated PCR of blunt DNA ends. Cell Death Differ 1997;4:66-75
136. Wyllie A, Morris R, Smith A, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67-77
137. Mynarcik D, Wei L, Komaroff E, et al. Chronic loss of subcutaneous adipose tissue in HIV-associated lipodystrophy may not be associated with accelerated apoptosis. J Acquir Immune Defic Syndr 2005;38(3):367-371